Vitrology
News
Vitrology new star of Scottish life sciences
From the Scotsman Journal - 13 November 2008
VITROLOGY, a Glasgow-based drug testing firm, was last night named as Scotland's "most promising young life science company".
The firm, which was set up in April 2007 and has already attracted 20 experienced staff, was given the prize by Nexxus, the West of Scotland Bioscience Network….… Laura Gordon, Director of the Glasgow-Edinburgh Collaboration and keynote speaker at the awards, said: "Life sciences is one of Scotland's true success stories, with Glasgow and Edinburgh home to 360 companies, employing more than 24,000 people in the industry."As these awards have showcased, our native talent can compete on a global level."
Vitrology is delighted to win the Award. Dr Archie Lovatt, Scientific Director, collected the award on behalf of the company said :
"It's wonderful to receive this recognition of our achievements to date and validation of our hopes for the future”
"Many international clients have approached us. We currently have contracts in place with a large number of companies in Europe and the USA, with several more about to be finalised. Good Laboratory Practice (GLP) accreditation from the MHRA was received earlier this year and last month we were accredited with Good Manufacturing Practice (GMP) compliance. This allows us to provide enhanced quality standards to meet increasing market demands, with a validated service offering increasing in size quarter by quarter. We're just delighted with the way things are going and winning this Award is just the icing on the cake."
For more information please see: http://www.nexxusscotland.com/news/award_ology
Further
success for Vitrology
22 September 2008
Following receipt
of a Good Laboratory Practice (GLP) accreditation from the
MHRA in March 2008, Glasgow based Vitrology - a biopharmaceutical
Contract Research Organisation (CRO) - are pleased to announce
they have had a successful Good Manufacturing Practice Compliance
(cGMP) Inspection from the MHRA also. The successful outcome
of the cGMP compliance inspection will allow them to implement
GMP testing compliance for lot release, thus offering enhanced
quality standards to meet increasing market demands.
The organisation's
GLP/cGMP dedicated facility has been custom designed specifically
for pre-clinical, clinical and production cell bank/viral
vaccine testing, and the batch release testing of biopharmaceutical
products intended for human and veterinary use. An extensive
- and expanding - range of validated microbiological, molecular
biology and virology assays is on offer to clients.
In addition, the
company will provide an online BioNet integrated into their
Client Relationship Management system, to allow clients and
scientists to download and upload information, as it becomes
available; interrogate data, for both ongoing and historical
work; manage the flow of work without burdening the organisation
with inefficient practices and put information "at the
fingertips" of the scientists and clients involved.
GLP and cGMP compliance
are vital in biopharmaceutical safety testing. To satisfy
Regulatory Authorities such as the US Food and Drug Administration
(FDA) and the European Medicines Evaluation Agency (EMEA),
all cell banks, viral banks, raw materials of animal origin,
bulk harvests and clinical drug products, must undergo extensive
safety testing to show they are free from bacteria, fungi,
Mycoplasma and viruses. Vitrology's state-of the-art laboratories
and systems provide testing solutions in all of these areas.
In recent months
the company has expanded its workforce to 20 and remains focused
on increasing its market share and expanding its services
for new biological therapeutics and vaccines.
For further information T: 0141 952 0022,
E : info@vitrologybiotech.com.
|
